Vizarsin

Country: Evrópusambandið

Tungumál: enska

Heimild: EMA (European Medicines Agency)

Kauptu það núna

Vara einkenni Vara einkenni (SPC)
24-02-2023
Opinber matsskýrsla Opinber matsskýrsla (PAR)
09-07-2012

Virkt innihaldsefni:

sildenafil

Fáanlegur frá:

Krka, d.d., Novo mesto

ATC númer:

G04BE03

INN (Alþjóðlegt nafn):

sildenafil

Meðferðarhópur:

Urologicals

Lækningarsvæði:

Erectile Dysfunction

Ábendingar:

Treatment of men with erectile dysfunction, which is the inability to achieve or maintain a penile erection sufficient for satisfactory sexual performance.In order for Vizarsin to be effective, sexual stimulation is required.

Vörulýsing:

Revision: 19

Leyfisstaða:

Authorised

Leyfisdagur:

2009-09-21

Upplýsingar fylgiseðill

                                66
B. PACKAGE LEAFLET
67
PACKAGE LEAFLET: INFORMATION FOR THE USER
VIZARSIN 25 MG FILM-COATED TABLETS
sildenafil
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS
MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.
-
Keep this leaflet. You may need to read it again.
-
If you have any further questions, ask your doctor or pharmacist.
-
This medicine has been prescribed for you only. Do not pass it on to
others. It may harm them,
even if their signs of illness are the same as yours.
-
If you get any side effects, talk to your doctor or pharmacist. This
includes any possible side
effects not listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET
1.
What Vizarsin is and what it is used for
2.
What you need to know before you take Vizarsin
3.
How to take Vizarsin
4.
Possible side effects
5.
How to store Vizarsin
6.
Contents of the pack and other information
1.
WHAT VIZARSIN IS AND WHAT IT IS USED FOR
Vizarsin contains the active substance sildenafil which belongs to a
group of medicines called
phosphodiesterase type 5 (PDE5) inhibitors. It works by helping to
relax the blood vessels in your
penis, allowing blood to flow into your penis when you get sexually
excited. Vizarsin will only help
you to get an erection if you are sexually stimulated.
Vizarsin is a treatment for adult men with erectile dysfunction,
sometimes known as impotence. This
is when a man cannot get, or keep a hard, erect penis suitable for
sexual activity.
2.
WHAT YOU NEED TO KNOW BEFORE YOU TAKE VIZARSIN
DO NOT TAKE VIZARSIN
-
If you are allergic to sildenafil or any of the other ingredients of
this medicine (listed in section
6).
-
If you are taking medicines called nitrates, as the combination may
lead to a dangerous fall in
your blood pressure. Tell your doctor if you are taking any of these
medicines which are often
given for relief of angina pectoris (or “chest pain”). If you are
not certain, ask your doctor or
pharmacist.
-
If you are using any of the medicines known as nitric oxide donors
such as amyl nitrite
                                
                                Lestu allt skjalið
                                
                            

Vara einkenni

                                1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE MEDICINAL PRODUCT
Vizarsin 25 mg film-coated tablets
Vizarsin 50 mg film-coated tablets
Vizarsin 100 mg film-coated tablets
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each film-coated tablet contains sildenafil citrate equivalent to 25
mg, 50 mg or 100 mg sildenafil.
Excipient with known effect:
_Vizarsin 25 mg film-coated tablets_
Each film-coated tablet contains 1.9 mg lactose (as monohydrate).
_Vizarsin 50 mg film-coated tablets_
Each film-coated tablet contains 3.8 mg lactose (as monohydrate).
_Vizarsin 100 mg film-coated tablets_
Each film-coated tablet contains 7.6 mg lactose (as monohydrate).
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Film-coated tablet.
Vizarsin 25 mg film-coated tablets: White, oblong tablets, marked
“25” on one side.
Vizarsin 50 mg film-coated tablets: White, oblong tablets, marked
“50” on one side.
Vizarsin 100 mg film-coated tablets: White, oblong tablets, marked
“100” on one side.
4.
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
Vizarsin is indicated in adult men with erectile dysfunction, which is
the inability to achieve or
maintain a penile erection sufficient for satisfactory sexual
performance.
In order for Vizarsin to be effective, sexual stimulation is required.
4.2
POSOLOGY AND METHOD OF ADMINISTRATION
Posology
_Use in adults:_
The recommended dose is 50 mg taken as needed approximately one hour
before sexual activity.
Based on efficacy and tolerability, the dose may be increased to 100
mg or decreased to 25 mg. The
maximum recommended dose is 100 mg. The maximum recommended dosing
frequency is once per
day. If Vizarsin is taken with food, the onset of activity may be
delayed compared to the fasted state
(see section 5.2).
Special populations
_Elderly_
Dosage adjustments are not required in elderly patients (≥ 65 years
old).
3
_Renal impairment:_
The dosing recommendations described in ‘Use in adults’ apply to
patients with mild to moderate
renal impairment (creat
                                
                                Lestu allt skjalið
                                
                            

Skjöl á öðrum tungumálum

Upplýsingar fylgiseðill Upplýsingar fylgiseðill búlgarska 24-02-2023
Vara einkenni Vara einkenni búlgarska 24-02-2023
Opinber matsskýrsla Opinber matsskýrsla búlgarska 09-07-2012
Upplýsingar fylgiseðill Upplýsingar fylgiseðill spænska 24-02-2023
Vara einkenni Vara einkenni spænska 24-02-2023
Opinber matsskýrsla Opinber matsskýrsla spænska 09-07-2012
Upplýsingar fylgiseðill Upplýsingar fylgiseðill tékkneska 24-02-2023
Vara einkenni Vara einkenni tékkneska 24-02-2023
Opinber matsskýrsla Opinber matsskýrsla tékkneska 09-07-2012
Upplýsingar fylgiseðill Upplýsingar fylgiseðill danska 24-02-2023
Vara einkenni Vara einkenni danska 24-02-2023
Opinber matsskýrsla Opinber matsskýrsla danska 09-07-2012
Upplýsingar fylgiseðill Upplýsingar fylgiseðill þýska 24-02-2023
Vara einkenni Vara einkenni þýska 24-02-2023
Opinber matsskýrsla Opinber matsskýrsla þýska 09-07-2012
Upplýsingar fylgiseðill Upplýsingar fylgiseðill eistneska 24-02-2023
Vara einkenni Vara einkenni eistneska 24-02-2023
Opinber matsskýrsla Opinber matsskýrsla eistneska 09-07-2012
Upplýsingar fylgiseðill Upplýsingar fylgiseðill gríska 24-02-2023
Vara einkenni Vara einkenni gríska 24-02-2023
Opinber matsskýrsla Opinber matsskýrsla gríska 09-07-2012
Upplýsingar fylgiseðill Upplýsingar fylgiseðill franska 24-02-2023
Vara einkenni Vara einkenni franska 24-02-2023
Opinber matsskýrsla Opinber matsskýrsla franska 09-07-2012
Upplýsingar fylgiseðill Upplýsingar fylgiseðill ítalska 24-02-2023
Vara einkenni Vara einkenni ítalska 24-02-2023
Opinber matsskýrsla Opinber matsskýrsla ítalska 09-07-2012
Upplýsingar fylgiseðill Upplýsingar fylgiseðill lettneska 24-02-2023
Vara einkenni Vara einkenni lettneska 24-02-2023
Opinber matsskýrsla Opinber matsskýrsla lettneska 09-07-2012
Upplýsingar fylgiseðill Upplýsingar fylgiseðill litháíska 24-02-2023
Vara einkenni Vara einkenni litháíska 24-02-2023
Opinber matsskýrsla Opinber matsskýrsla litháíska 09-07-2012
Upplýsingar fylgiseðill Upplýsingar fylgiseðill ungverska 24-02-2023
Vara einkenni Vara einkenni ungverska 24-02-2023
Opinber matsskýrsla Opinber matsskýrsla ungverska 09-07-2012
Upplýsingar fylgiseðill Upplýsingar fylgiseðill maltneska 24-02-2023
Vara einkenni Vara einkenni maltneska 24-02-2023
Opinber matsskýrsla Opinber matsskýrsla maltneska 09-07-2012
Upplýsingar fylgiseðill Upplýsingar fylgiseðill hollenska 24-02-2023
Vara einkenni Vara einkenni hollenska 24-02-2023
Opinber matsskýrsla Opinber matsskýrsla hollenska 09-07-2012
Upplýsingar fylgiseðill Upplýsingar fylgiseðill pólska 24-02-2023
Vara einkenni Vara einkenni pólska 24-02-2023
Opinber matsskýrsla Opinber matsskýrsla pólska 09-07-2012
Upplýsingar fylgiseðill Upplýsingar fylgiseðill portúgalska 24-02-2023
Vara einkenni Vara einkenni portúgalska 24-02-2023
Opinber matsskýrsla Opinber matsskýrsla portúgalska 09-07-2012
Upplýsingar fylgiseðill Upplýsingar fylgiseðill rúmenska 24-02-2023
Vara einkenni Vara einkenni rúmenska 24-02-2023
Opinber matsskýrsla Opinber matsskýrsla rúmenska 09-07-2012
Upplýsingar fylgiseðill Upplýsingar fylgiseðill slóvakíska 24-02-2023
Vara einkenni Vara einkenni slóvakíska 24-02-2023
Opinber matsskýrsla Opinber matsskýrsla slóvakíska 09-07-2012
Upplýsingar fylgiseðill Upplýsingar fylgiseðill slóvenska 24-02-2023
Vara einkenni Vara einkenni slóvenska 24-02-2023
Opinber matsskýrsla Opinber matsskýrsla slóvenska 09-07-2012
Upplýsingar fylgiseðill Upplýsingar fylgiseðill finnska 24-02-2023
Vara einkenni Vara einkenni finnska 24-02-2023
Opinber matsskýrsla Opinber matsskýrsla finnska 09-07-2012
Upplýsingar fylgiseðill Upplýsingar fylgiseðill sænska 24-02-2023
Vara einkenni Vara einkenni sænska 24-02-2023
Opinber matsskýrsla Opinber matsskýrsla sænska 09-07-2012
Upplýsingar fylgiseðill Upplýsingar fylgiseðill norska 24-02-2023
Vara einkenni Vara einkenni norska 24-02-2023
Upplýsingar fylgiseðill Upplýsingar fylgiseðill íslenska 24-02-2023
Vara einkenni Vara einkenni íslenska 24-02-2023
Upplýsingar fylgiseðill Upplýsingar fylgiseðill króatíska 24-02-2023
Vara einkenni Vara einkenni króatíska 24-02-2023

Leitaðu viðvaranir sem tengjast þessari vöru

Skoða skjalasögu